PSP001 - A First-in-disease human PEGIFN-λ Chimera
| Status：Q4 2019, FDA Pre-IND Meeting; |
| Date:2019-08-05 18:47:57 | Visits： |
| Prev:Jan 7th, 2021 FDA IND Submission; Next:Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection |
